Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease
Moustafa Abdou, Author and Founder of AskHematologist.com, shared a post on LinkedIn:
”Cold Agglutinin Disease (CAD)
Cold Agglutinin Disease is a rare but clinically significant complement-mediated autoimmune hemolytic anemia driven by cold-reactive IgM antibodies.
What makes CAD particularly important is its dual presentation: chronic hemolysis alongside cold-induced circulatory symptoms such as acrocyanosis and Raynaud-like changes.
Diagnosis requires a high index of suspicion, with a characteristic C3d-positive direct antiglobulin test and evidence of complement activation.
Management has evolved significantly in recent years.
While cold avoidance and rituximab-based therapy remain important, targeted complement inhibition (e.g. sutimlimab) is transforming outcomes in selected patients.
Early recognition is key to preventing complications and improving quality of life.”
Stay updated with Hemostasis Today.
-
Jul 17, 2026, 10:12Julien Perrin: Presenting Thalassemia Coagulation Research at ISTH 2026
-
Jul 17, 2026, 10:08Cihan Ay: Thank you for making ISTH 2026 such a remarkable congress
-
Jul 17, 2026, 10:06Laura Cunliffe: That Is a Wrap for Meg and Me at ISTH 2026 in Paris
-
Jul 17, 2026, 10:03Roberta Gualtierotti: Updating on the Standardization of ultrasound definitions in hemophilic arthropathy at the ISTH 2026
-
Jul 17, 2026, 09:57Hrushikesh Vyas – A Wonderful Week Presenting Inherited Thrombocytopenia Research at ISTH 2026
-
Jul 17, 2026, 09:42Samin Mohsenian: Proud to Receive a Top Poster Award at ISTH 2026
-
Jul 17, 2026, 09:36Wolfgang Miesbach: A Landmark Case of Supratherapeutic FIX Following Gene Therapy Presented at ISTH 2026
-
Jul 17, 2026, 09:28Lisa Astorga: Leaving ISTH 2026 Inspired by the Global Thrombosis and Hemostasis Community
-
Jul 17, 2026, 09:23Maxime Dely: Honored to Reach My 6th Plasma Donation of 2026